OTSUKA PHARMACEUTICAL CO., LTD.

OTSUKA PHARMACEUTICAL CO., LTD. logo
🇯🇵Japan
Ownership
Public, Subsidiary
Established
1964-01-01
Employees
101
Market Cap
-
Website
http://www.otsuka.co.jp
Clinical Trials
Related News

Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

First Posted Date
2014-06-20
Last Posted Date
2017-10-16
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
150
Registration Number
NCT02168920

Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

First Posted Date
2014-04-09
Last Posted Date
2015-04-22
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
30
Registration Number
NCT02108288

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

First Posted Date
2014-04-07
Last Posted Date
2015-12-28
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
193
Registration Number
NCT02105285

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

First Posted Date
2014-04-07
Last Posted Date
2015-12-21
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
237
Registration Number
NCT02105272

A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
Drug: ASC-01
First Posted Date
2014-03-17
Last Posted Date
2021-06-03
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
50
Registration Number
NCT02088697
Locations
🇯🇵

Osaka Pharmacology Clinical research Hospital, Osaka, Japan

A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer

First Posted Date
2014-03-12
Last Posted Date
2021-10-18
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
94
Registration Number
NCT02085460

A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)

Phase 1
Completed
Conditions
Atrial Fibrillation
Interventions
Drug: Placebo
Drug: OPC-108459
First Posted Date
2014-02-21
Last Posted Date
2018-11-05
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
48
Registration Number
NCT02069119

Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: ASC-01
Drug: Placebo
First Posted Date
2014-01-28
Last Posted Date
2018-05-21
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
412
Registration Number
NCT02046564

A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Acute Myeloid Leukemia
Interventions
Drug: OCV-501
Drug: Placebo
First Posted Date
2013-10-14
Last Posted Date
2021-03-26
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
134
Registration Number
NCT01961882

A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
First Posted Date
2013-09-13
Last Posted Date
2017-06-28
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
68
Registration Number
NCT01942148
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy